CRP and Epstein-Barr virus infection: In the bivariate analysis that included the total study population (n = 139) and that compared the profile of EBV infection (lytic activity and latency) with clinical laboratory variables (clinical diagnosis, age group, platelet, lymphocyte, ESS, CRP, symptoms) and therapeutic management (medicines used, daily dosage and treatment time) of patients, there was no statistically significant difference between patients with active or latent EBV (Table 2).